ANI Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ANIP Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
17 Dec 24	SellUS$418,425	Stephen Carey	Individual	7,500	US$55.79
26 Nov 24	SellUS$202,942	Nikhil Lalwani	Individual	3,481	US$58.30
15 Nov 24	SellUS$375,050	Christopher Mutz	Individual	6,500	US$57.70
05 Jun 24	SellUS$199,995	Ori Gutwerg	Individual	2,985	US$67.00
04 Jun 24	SellUS$317,900	Stephen Carey	Individual	5,000	US$63.58
21 May 24	SellUS$123,220	Christopher Mutz	Individual	2,000	US$61.61
16 May 24	SellUS$127,740	Renee Tannenbaum	Individual	2,000	US$63.87
14 May 24	SellUS$1,101,821	Nikhil Lalwani	Individual	16,669	US$66.10
12 Mar 24	SellUS$4,982,750	MVP Capital Partners	Company	75,000	US$67.50
11 Mar 24	SellUS$510,438	Stephen Carey	Individual	7,787	US$65.55
08 Mar 24	SellUS$2,991,469	Nikhil Lalwani	Individual	45,257	US$67.13
07 Mar 24	SellUS$1,615,313	James Marken	Individual	24,338	US$66.37
05 Mar 24	SellUS$330,000	Christopher Mutz	Individual	5,000	US$66.00
04 Mar 24	SellUS$456,400	Antonio Pera	Individual	7,000	US$65.20

Insider Trading Volume

Insider Buying: ANIP insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ANIP?
Owner Type	Number of Shares	Ownership Percentage
State or Government	8,144	0.0354%
Private Companies	637,620	2.77%
VC/PE Firms	1,419,381	6.16%
Individual Insiders	1,525,071	6.62%
Institutions	19,437,298	84.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.

Top Shareholders

Top 25 shareholders own 79.87% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
13.8%	BlackRock, Inc.	2,689,712	US$143.5m	1.25%	no data
7.27%	MVP Capital Partners	1,419,381	US$75.7m	0%	100.0%
6.9%	The Vanguard Group, Inc.	1,348,111	US$71.9m	-6.41%	no data
3.6%	State Street Global Advisors, Inc.	703,843	US$37.6m	9.1%	no data
3.54%	Goldman Sachs Group, Investment Banking and Securities Investments	691,566	US$36.9m	1,600%	0.02%
3.36%	Dimensional Fund Advisors LP	655,310	US$35.0m	3.98%	0.01%
3.24%	Esjay Llc	632,620	US$33.8m	-7.32%	no data
3.02%	Ranger Investment Management, L.P.	589,688	US$31.5m	46.4%	2.01%
2.91%	Pacer Advisors, Inc.	568,343	US$30.3m	23,300%	0.07%
2.75%	Global Alpha Capital Management Ltd.	536,450	US$28.6m	1.8%	0.79%
2.71%	Citadel Advisors LLC	529,877	US$28.3m	43.9%	0.03%
2.71%	Millennium Management LLC	529,752	US$28.3m	130%	0.02%
2.59%	Deep Track Capital, LP	504,828	US$26.9m	8.31%	0.87%
2.52%	Macquarie Investment Management Business Trust	491,647	US$26.2m	26.7%	0.03%
2.43%	William Blair Investment Management, LLC	474,828	US$25.3m	-2.97%	0.03%
2.3%	Tang Capital Management, LLC	450,000	US$24.0m	0%	1.83%
2.18%	Geode Capital Management, LLC	425,225	US$22.7m	4.24%	no data
1.9%	Nikhil Lalwani	370,378	US$19.8m	-0.93%	no data
1.8%	JPMorgan Chase & Co, Brokerage and Securities Investments	350,669	US$18.7m	934%	0.01%
1.64%	UBS Asset Management AG	320,439	US$17.1m	328%	no data
1.56%	Morgan Stanley, Investment Banking and Brokerage Investments	303,843	US$16.2m	74.8%	no data
1.38%	Soleus Capital Management, L.P.	269,000	US$14.4m	0%	1.15%
1.28%	Charles Schwab Investment Management, Inc.	250,346	US$13.4m	3.67%	no data
1.26%	Renaissance Technologies LLC	245,102	US$13.1m	56.3%	0.02%
1.24%	Chad Gassert	242,905	US$13.0m	-7.61%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 02:35
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ANI Pharmaceuticals, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dewey Steadman	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.
Timothy Chiang	Capital One Securities, Inc.